Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker

New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a marker of treatment response in these autoimmune diseases.:

Source: Neurology Read More

Previous PostFDA Action Update, July 2025: Approval, Label Update, Complete Response Letter
Next PostOverviewing Promising Large-Scale Data on GLP-1 RAs in Idiopathic Intracranial Hypertension: Dennis Rivet, MD

Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker

Previous PostFDA Action Update, July 2025: Approval, Label Update, Complete Response Letter

Next PostOverviewing Promising Large-Scale Data on GLP-1 RAs in Idiopathic Intracranial Hypertension: Dennis Rivet, MD

Related Posts

<![CDATA[Nipocalimab Shows Sustained Disease Control and Symptom Improvement in 2-Year Extension Study]]>

<![CDATA[Key Takeaways on Neurorehabilitation Innovation at 2026 AAN: Nirmal Surya, MD, DM]]>

<![CDATA[Neutrophil-to-Lymphocyte Ratio as a Scalable Signal in Dementia Risk Assessment]]>

Categories